Use of abciximab: Comparative economic data

American Heart Journal

Volumn 137, Issue 5, 1999, Pages

  Mark, Daniel B ^a   Simons, Tracey A ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ECONOMIC ASPECT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HOSPITAL COST; PHARMACOECONOMICS; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; UNITED STATES;

EID: 0032913360     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70445-X     Document Type: Conference Paper

References (8)

1. 1. Mark DB. Medical economics for interventional cardiology. In: Topol EJ, editor. Textbook of interventional cardiology, 3rd ed. Philadelphia: WB Saunders; 1998:889-909.
2. 2. Pepine CJ, Mark DB, Bourassa MG, et al. Cost implications for treatment of cardiac ischemia: an ancillary study from Asymptomatic Cardiac Ischemia Pilot (ACIP). Am Heart J 1998. (Submitted).
3. 3. Hlotky MA, Rogers WJ, Johnstone I, et al, for the BARI Investigators. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 1997; 336:92-9.
4. 4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330: 956-61.
5. 5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
6. 6. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. Circulation 1996;94: 629-35.
7. 7. Peterson ED, Lansky AJ, Muhlbaier LH, et al. Evolving trends in angioplasty device selection: a National Cardiovascular Network (NCN) database report. J Am Coll Cardiol 1997;29:495A.
8. 8. Cowper PA, Peterson ED, Zidar JP, DeLong ER, McCants CB, Mark DB. Coronary stent costs completely recouped in six months. Circulation 1997;96:456A.